Obstructive sleep apnea (OSA) is a sleep disorder that impacts millions globally. In the United States alone, it is estimated that approximately 39 million adult Americans suffer from sleep apnea, with many cases undiagnosed. Men are more likely to have this condition than women, reflecting differences in fat distribution, airway anatomy, and hormone profiles that influence sleep and breathing patterns.
In recent years, Semaglutide has emerged as a noteworthy ingredient in medications that address metabolic health and weight loss. Many of these medications, including Ozempic®, were originally developed to manage blood sugar levels in patients with Type 2 Diabetes, but were later found to have a big role in supporting weight management.
At HDRx, we are committed to providing high-quality, customized medication solutions like compounded Semaglutide, for those affected by the Ozempic/Wegovy shortage.
Many patients suffer from difficult-to-address gastrointestinal (GI) and rectal health conditions like hemorrhoids and anal fissures.
As medication development continues to advance in the specialty of Ear, Nose, and Throat (ENT), more patients are finally finding what works for their challenging conditions, especially for those suffering from seasonal allergies, severe allergies, and other conditions.
Although developed for diabetes, semaglutide has recently gained popularity due to the public’s discovery of its significant weight loss side effects, with patients flocking to get it.
Regardless of the medications involved, the close partnership between a podiatrist and a compounding pharmacy provides ...
